Reference: GILA/ID/IPO-002/CHEM
Board seat: Independent Director, Non-Executive
Primary board location: Vadodara/Bharuch industrial corridor, Gujarat
Meeting model: Six board cycles, six risk/project reviews and quarterly plant assurance visits
Mandate type: Pre-IPO Board Build & IPO Readiness
Status: Confidential live-search specification; client identity released only after conflict clearance and NDA.
The anonymised enterprise
A multi-plant manufacturer of fluorination intermediates and performance additives serving agrochemical, electronics and industrial customers, with exports contributing more than half of revenue.
Revenue is approximately ₹2,200–3,200 crore. A new hazardous-chemistry block represents the largest capital programme in the company’s history; a financial sponsor plans a partial exit through an IPO within six quarters.
The board problem and strategic reason for appointment
Public investors will test whether margin expansion comes from defensible chemistry or from under-provisioned environmental and process-safety risk. One delayed brownfield block and a near-miss at a legacy plant make capital discipline and operational assurance central to valuation.
The board is not buying a credential. It is appointing an independent decision-maker who can convert this problem into a governed sequence of choices, evidence and accountability. Success will be judged by the quality of decisions and control improvement, not by the number of recommendations made.
Board position, authority and interfaces
Member of Audit and intended Chair of the Risk/Sustainability Committee. The seat receives independent process-safety assurance and has authority to request a third-party pre-start-up review.
The appointee will have direct, unfiltered access to the Company Secretary and to the relevant control-function leaders. Any advisory support requested by the board must remain management-executed: the director sets questions, tolerances and evidence standards, but does not become an executive or consultant.
First 12–18 month strategic charter
- Establish stage-gate governance for the new block, including contingency, commissioning readiness and benefits ownership; commission a bow-tie review of the three highest-consequence reaction scenarios; reconcile consent-to-operate conditions, hazardous-waste manifests and legacy remediation provisions; challenge customer and molecule concentration, including the effect of an end-market ban or patent expiry
- Convert the listing workplan into a board-owned assurance map: each offer-document assertion, restated-financial dependency, material contract, litigation disclosure and KPI must have an executive owner, an independent challenge point and dated evidence.
- Create a post-listing operating rhythm before filing: quarterly close rehearsals, UPSI controls, disclosure escalation, analyst-communication discipline, committee calendars and a board-paper standard capable of surviving public scrutiny.
Decision profile sought
Essential evidence
- Senior chemical-industry operator or process-safety leader with hazardous batch-plant experience; capital-project governance at ₹500 crore+ scale; listed-company or IPO committee experience
Differentiators
- International Responsible Care, EU REACH or major-hazard regulatory exposure; experience after a serious process-safety event
GILA will assess completed Indian capital-markets exposure, judgement under filing pressure, and the ability to distinguish genuine governance readiness from transaction theatre. Candidates should expect a case discussion based on an ambiguous board decision from this mandate, not a career-history interview alone.
Independence, suitability and downside diligence
The search will apply Section 149(6), Sections 164–165, Schedule IV and the applicable listing or sector rules to the entity’s legally verified status at the appointment date. Databank/proficiency status, listed-entity directorship and committee ceilings, pecuniary relationships, relatives’ interests, recent audit/advisory work and interlocking directorships will be checked. The appointment is subject to formal legal and secretarial confirmation; this posting is not a substitute for that determination.
Mandate-specific screens: Board or consulting ties to direct molecule competitors; commercial links to the EPCM contractor or environmental adviser; undisclosed land interests near either site.
Before accepting the seat, the candidate will receive under NDA the latest board composition, committee charters, material litigation/regulatory schedule, related-party map, last audited accounts, current D&O policy and the specific risk papers necessary to make an informed liability assessment.
Twelve-month outcomes
The board expects a board with a defensible pre-filing record, no last-minute committee architecture, and a credible first-year listed-company calendar. For this particular seat, the evidence will be:
- Board-approved major-accident risk tolerances and verified critical controls; capex forecast accuracy and start-up criteria independently assured; environmental liabilities and customer concentration reflected without inconsistency in offer materials
Commitment, protection and economics
- Expected load: 32–40 days during construction and filing; 24–28 in steady state.
- Terms: Five-year appointment; statutory sitting fees/commission; separate site-visit fee where permitted; robust pollution and securities-claim D&O extensions.
- Protection: Appointment letter, deed of indemnity where legally available, appropriate D&O cover including discovery/run-off terms, access to independent advice under the board-approved protocol, and complete minuting of dissent.
- Equity: No stock options where the appointment is legally an independent-director seat subject to Section 149(9). Any private-company structure outside that perimeter will be expressly classified and separately advised; no equity is implied by this posting.
Search process
Conflict pre-clearance → GILA/SYMPHONY™ board-fit interview → mandate case → document-led diligence under NDA → references from board peers and control functions → NRC/owner interviews → statutory, regulatory and reputation checks → board recommendation. Candidate consent, disclosures and appointment approvals will follow the law and the entity’s constitutional documents.